TITLE

Advisers recommend improved labeling for phenytoin, fosphenytoin

AUTHOR(S)
Traynor, Kate
PUB. DATE
December 2010
SOURCE
American Journal of Health-System Pharmacy;12/15/2010, Vol. 67 Issue 24, p2086
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article presents the recommendation for improved labeling of fosphenytoin, a prodrug of phenytoin, by a large group of advisers to the U.S. Food and Drug Administation (FDA). It discusses whether phenytoin and fosphenytoin can cause purple glove syndrome (PGS). It also provides information on fosphenytoin including dosage, indication and contraindication.
ACCESSION #
56584754

 

Related Articles

  • News Briefs.  // American Journal of Health-System Pharmacy;5/15/2014, Vol. 71 Issue 10, p778 

    This section offers news briefs concerning the pharmaceutical sector, as of May 2014, including the marketing approval given by the U.S. Food and Drug Administration on Nexium 24HR, the name change of the ethiodized oil injection drug Ethiodol to Lipiodol, and the death of Michael S. Flagstad, a...

  • Approvals, Submission, and Important Labeling Changes for US Marketed Pharmaceuticals. Baker, Danial E. // Hospital Pharmacy;Aug2012, Vol. 47 Issue 8, p648 

    The article discusses new drugs, new indications and dosage forms as well as new drug/biologics license applications filed by the manufacturer and safety-related changes in labeling or use approved by the U.S. FDA from May 16 through June 15, 2012.

  • FDA has updated labeling for antiepileptic drugs treating epilepsy.  // Drug Formulary Review;Jul2009, Vol. 25 Issue 7, p83 

    The article reports on the approval of the U.S. Food and Drug Administration (FDA) on the updated labeling for antiepileptic drugs used to treat epilepsy and psychiatric disorders. It cites that the FDA has conducted clinical studies of such drugs, which have shown consistent risk of suicidal...

  • Approvals, Submission, and Important Labeling Changes for US Marketed Pharmaceuticals. Baker, Danial E. // Hospital Pharmacy;May2014, Vol. 49 Issue 5, p482 

    This monthly feature will help readers keep current on new drugs, new indications, dosage forms, and safety-related changes in labeling or use. Efforts have been made to ensure the accuracy of this information; however, if there are any questions, please let me know at danial.baker@wsu.edu.

  • New therapeutic agents marketed in the second half of 2011: Part 1. Hussar, Daniel A. // Pharmacy Today;Feb2012, Vol. 18 Issue 2, p55 

    Objective: To provide information regarding the most important properties of the new therapeutic agents marketed in the second half of 2011. Data sources: Product labeling supplemented selectively with published studies and drug information reference sources. Data synthesis: 13 new therapeutic...

  • Approvals, Submission, and Important Labeling Changes for US Marketed Pharmaceuticals. Baker, Danial E. // Hospital Pharmacy;Nov2012, Vol. 47 Issue 11, p883 

    The article presents information on new drugs and indications as well as dosage forms and safety-related changes in labeling or use approved by the U.S. FDA August 18 through September 14, 2012. These include new drugs like bosutinib (Bosulif, Pfizer), new dosage forms for Everolimus (Afinitor...

  • Approvals, Submission, and Important Labeling Changes for US Marketed Pharmaceuticals. Baker, Danial E. // Hospital Pharmacy;Jul2013, Vol. 48 Issue 7, p595 

    Several tables depicting the U.S. Food and Drug Administration (FDA)-related drug information are presented including one listing the new drugs approved by the FDA from April 16-May 17, 2013, another showing the FDA-approved new dosage forms during the same period and one on the labeling changes.

  • Approvals, Submission, and Important Labeling Changes for US Marketed Pharmaceuticals. Baker, Danial E. // Hospital Pharmacy;Jun2013, Vol. 48 Issue 6, p512 

    A table is presented which lists new drugs, new indications, dosage forms, and safety-related changes in labeling or use that are approved by U.S. Food and Drug Administration (FDA).

  • Antidepressants: new black box warnings unlikely to significantly threaten sales.  // PharmaWatch: CNS;Jun2007, Vol. 6 Issue 6, p11 

    The article announces the proposal of the U.S. Food and Drug Administration (FDA) regarding the extension of the existing black box warning on antidepressant labels. The proposal includes warnings about the increased risks of suicidality in 18 to 24-year-old individuals. It is stated that the...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics